Here’s what you should know:
1. The approval will be contingent upon Takeda divesting Shire’s gastrointestinal pipeline compound, Reuters reports. The compound overlaps with Takeda’s own inflammatory bowel disease drug, Entyvio.
2. Entyvio is Takeda’s biggest selling drug.
3. After earning EU approval, Takeda must earn shareholder approval.
4. Takeda scheduled a general meeting Dec. 5, to hold a shareholder vote, the Financial Times reports.
5. A portion of Takeda’s shareholders are vocal opponents of the deal, buta past procedural vote on the deal passed with little resistance.
More articles on supply chain:
HonorHealth plans to open $170M hospital, ASC in 2020 — 3 highlights
4 things surgeons should know when selecting an ASC for procedures
Medical Facilities Corp. increases surgical cases 47.4% in Q3 — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.